Ozempic is linked to a potentially higher risk of vision loss in some studies. Doctors explain how GLP-1 drugs for diabetes ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy. There was ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition. Last month, the European Medicines ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...

The lawsuit said about four months later, Engel was diagnosed with nonarteritic anterior ischemic optic neuropathy, or NAION, a condition in which a loss of blood flow to the optic nerve causes ...